$AEHR

POSEDEL RHEA J sold $1.1M of AEHR (indirect holdings)

POSEDEL RHEA J (Director) sold 8,413 indirectly-held shares of AEHR TEST SYSTEMS (AEHR) at $130.00 ($1.09M total) on 2026-08-12.

Original reporting
SEC EDGAR · POSEDEL RHEA J
Published Aug 13, 2026, 9:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

The only new fact is the size, price, and timing of the director’s sale. It does not provide new information about AEHR’s business performance or outlook.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The transaction is labeled indirect and no 10b5-1 plan is indicated; traders may want to check for other recent insider transactions or subsequent filings for context.

Relevance 6/10Novelty 5/10Timing: filed after-hours on 2026-08-13, covering a sale dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for AEHR, reported by a director via an indirect holding.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR director Rhea J Pose del sold 8,413 shares at $130 on 2026-08-12, totaling about $1.09M, via an indirect holding.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing is a Form 4 open-market sale with no 10b5-1 plan stated, but it does not include new operating, guidance, or regulatory information.

Market effects

Minimal; insider-sale filings rarely reset sector expectations without accompanying company news.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management, especially since the filing does not cite any adverse company development.

Key entities

  • AEHR

    AEHR Test Systems, the company whose director transaction is disclosed.

  • POSEDEL RHEA J

    Director reporting an open-market sale of AEHR shares via an indirect holding.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRMed

AEHR Stock Rides AI Order Wave Amid Volatility

Aehr Test Systems (AEHR) stock rose 13.28% following strong earnings and a positive outlook for semiconductor test demand. The company reported $50M in revenue, $18.8M in quarterly revenue, and a net income of $1.39M. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI production. The stock has shown volatility, with a recent drop of 9.5-10.5% in a single session. Insiders have sold shares but maintain significant holdings. AEHR is actively presenting a

$AEHRHigh

AEHR Stock Rallies As AI Orders And Wall Street Support Build

Aehr Test Systems (AEHR) stock rose 11.71% due to strong AI-related demand. The company reported $18.8M in revenue with a 35.3% gross margin. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI chip production. The company has a strong balance sheet and a $22M follow-on order from a major customer.

$AEHRHigh

AEHR Stock Rallies As AI Test Orders And Wall Street Support Grow

Aehr Test Systems (NASDAQ: AEHR) stock rose 11.73% on growing AI test demand. The company secured a $22M follow-on order for AI chip testing equipment. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's unique position in AI production testing. The stock has high volatility, with a strong balance sheet but negative EBIT margins.